Pyoderma gangrenosum (PG) is an uncommon condition that is associated with a systemic disease in 50% of patients. The condition may be associated with a monoclonal gammopathy, usually of the IgA type. It is rare for PG to be associated with multiple myeloma.
Observations:
We report the case of an 83-year-old man with PG associated with an IgA myeloma. The myeloma was discovered after the diagnosis of PG had been made. This is the 22nd case of multiple myeloma associated with PG, and only the 14th case of PG with an IgA myeloma.
Conclusions:
We should be aware of the potential association of multiple myeloma with PG, and consider doing a serum protein electrophoresis in the evaluation of patients with PG.
Get full access to this article
View all access options for this article.
References
1.
PowellFCSchroeterALSuWPD. Pyoderma gangrenosum: A review of 86 patients. Q J Med1985; 217:173–186.
2.
BrunstingLAGoeckermanWHO'LearyPA. Pyoderma (ecthyma) gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol1930; 22: 655–680.
3.
PerryHOBrunstingLA. Pyoderma gangrenosum: A clinical study of 19 cases. Arch Dermatol1957; 75:380–386.
4.
PowellFCSuDPPerryHO. Pyoderma gangrenosum classification and management. J Am Acad Dermatol1996; 34:395–409.
PowellFCSchroeterALSuWPD. Pyoderma gangrenosum and monoclonal gammopathy. Arch Dermatol1983; 119: 468–471.
7.
HoltPJADaviesMGSaundersKC. Pyoderma gangrenosum: Clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine1980; 59:114–133.
8.
van der SluisI. Two cases of pyoderma (ecthyma) gangrenosum associated with the presence of an abnormal serum protein (beta 2A-paraprotein): With a review of the literature. Dermatologica1966; 132:409–424.
9.
PrystowskyJHKahnSNLazarusGS. Present status of pyoderma gangrenosum. Arch Dermatol1989; 125:57–63.
10.
JablonskaPSStachowADabrowskaH. Rapports entre la pyodermite gangreneuse et le myèlome. Ann Dermatol Syphiligr1967; 94:121–132.
11.
ThivelotJPelleratJHermierC. Myelome avec agammaglobulinémie revelé par une pyodermite phagédenique. Lyon Med1964; 212:107–112.
12.
RocklHKnedelMSchroplF. Über das Vorkommen von Paraproteinämic bei Pyoderma ulcerosa serpiginosa (Pyoderma gangraenosum — Dermatitis ulcerosa). Hautarzt1964; 15:165–171.
13.
SchallreuterKU. An uncommon onset of myeloma. J Am Acad Dermatol1985; 13:819–821.
14.
SanchezYECabreJ. Pyoderma gangrenosum con mieloma IgA lambda y deficit de la inmunidad celular. Actas Dermo-Sifiliograficas1980; 71:35–40.
15.
StoneMSLyckholmLJ. Pyoderma gangrenosum and subcorneal pustular dermatosis: Clues to underlying immunoglobulin A myeloma. Am J Med1996; 100:663–664.
16.
KoisJMSextonFMLookingbillDP. Cutaneous manifestations of multiple myeloma. Arch Dermatol1991; 127:69–74.
ImhofJWSchutterVleugels GJNHartHC. Monoclonal gammopathy (IgG) and chronic ulcerative dermatitis (phagedenic pyoderma). Acta Med Scand1969; 186:289–292.
19.
ZaabelM. Pyoderma gagraenosum mit IgG-Paraproteinämie bei Plasmozytom. Hautarzt1976; 27:603–605.
20.
MollerHWaldenstromJGZettervallO. Pyoderma gangraenosum (dermatitis ulcerosa) and monoclonal (IgA) globulin healed after melphalan treatment. Case report and review of the literature. Acta Med Scand1978; 203:293–296.
21.
CowanMA. Ulceration of the skin in multiple myeloma. Brit J Dermatol1961; 73:415–418.
22.
KresbachG. Pyoderma gangraenosum — Dermatitis ulcerosa. Z Haut Geschl Krankh1971; 46:292–293.
23.
DuperratBPuissantADavidV. Pyodermite phagedenique avec IgA monoclonale et plasmocytome osseux isolé. Bull Soc Fr Derm Syph1972; 79:615–616.
24.
KyleRA. Monoclonal gammopathy of undetermined significance. Am J Med1978; 64:814–826.
25.
LongoDL. Plasma cell disorders. In: IsselbacherKJMartinJBBraunwaldE, eds. Harrison's principles of internal medicine. New York: McGraw Hill, 1994:1618–1625.
26.
JonesRR. Cutaneous manifestations of paraproteinemia. Part II. Br J Dermatol1981; 104:209–220.
27.
Van EppsDEWilliamsRL. Suppression of leucocyte Chemotaxis by human IgA myeloma components. J Exp Med1976; 144:1227–1242.
28.
NorgaardO. Three cases of multiple myeloma in which the preclinical asyptomatic phases persisted throughout 15–24 years. Br J Cancer1971; 25:417–422.
